Abstract:Introduction Outflow graft stenosis (OGS) has been reported in patients with the HeartMate 3 left ventricular assist device (LVAD) as a result of biodebris accumulation outside the graft. As a result, patients may experience unexpected low-flow alarms, relapse of heart failure symptoms, cardiogenic shock, or even death. Different cutoff values are used to define OGS, and the literature also lacks clarity regarding how the severity of OGS relates to potential clinical outcomes. Purpose The purpose of this study is to describe the prevalence, clinical presentation, outcomes, and treatments associated with different degrees of HeartMate 3 LVAD OGS. Methods In this single-centre retrospective cohort study, we reviewed all HeartMate 3 patients between March 2016 and December 2023 with an available computed tomographic angiogram (CTA) sufficient to assess the outflow graft lumen. Before 2022, CTAs were conducted only at baseline after LVAD implantation and on specific indications, such as low-flow alarms. However, since 2022, routine biennial CTAs have been performed for all patients, starting 2 years post-LVAD implantation, reflecting increased awareness of LVAD OGS. We determined the percentage of lumen narrowing by measuring perpendicular to the outflow graft in different axes, categorizing as: no stenosis (0-25%), mild stenosis (25-50%), moderate stenosis (50-75%), and severe stenosis (>75%). Results We included 135 patients (median age: 53 years, 63% male), with a total of 330 available CTA scans. Throughout the study period (median FU of 31.8 months, IQR:11-43), evidence of OGS was observed in 16 (11.8%) patients: 8 (5.9%) with mild stenosis, 6 (4.4%) with moderate stenosis, and 2 (1.5%) with severe stenosis. The median time to mild stenosis, moderate stenosis, and severe stenosis was 2.5, 3.9, and 4.9 years respectively. Figure illustrates the prevalence, clinical presentation and treatment of various degrees of OGS. Among patients with mild stenosis, 75% (6/8) were detected incidentally during routine CTA scans, while 50% (3/6) of those with moderate stenosis presented with low-flow alarms. Only 7.6% (9/119) of patients with no stenosis experienced low-flow alarms. Mild and moderate stenosis were not associated with mortality compared to no stenosis (p>0.05), but severe stenosis was (p<0.05). Five patients underwent stenting, and one patient underwent surgery for outflow graft stenosis. Conclusions LVAD OGS is a significant late complication affecting approximately one in eight patients, with potentially severe consequences. Severe stenosis is associated with higher mortality compared to no stenosis. The true prevalence may be underestimated due to delayed radiological surveillance initiation. CTA plays a pivotal role as a non-invasive diagnostic step to identify OGS and systematic screening may be warranted. Endovascular stenting or surgery can effectively treat patients with OGS.

Extrinsic Outflow Graft Obstruction of the HeartMate 3 LVAD: A State-of-the-Art Review

A multicenter evaluation of external outflow graft obstruction with a fully magnetically levitated left ventricular assist device

Outflow graft obstruction in patients with the HM 3 LVAD: A percutaneous approach

Outflow graft obstruction after left ventricular assist device implantation: a retrospective, single-centre case series

Outcomes of outflow graft stenting in HeartMate 3 left ventricular assist devices: A systematic review and individual patient data meta‐analysis

Haemodynamic significance of extrinsic outflow graft stenoses during HeartMate 3™ therapy

Outflow graft stenosis after left ventricular assist device implantation: the rotterdam experience

Outflow Graft Tamponade: An Underrecognized Cause of Obstruction

Surgical intervention for left ventricular assist device outflow graft obstruction due to external compression

Percutaneous endovascular intervention for left ventricular assist device outflow graft obstruction: A single-center experience

Evolution of Mechanical Circulatory Support for advanced heart failure

HeartMate 3: Analysis of Outcomes and Future Directions

Percutaneous Stenting Of The Bend Relief And Proximal Segment Outflow Graft Of Durable Left Ventricular Assisted Device

Nine Years of Continuous Flow LVAD (HeartMate 3): Survival and LVAD-Related Complications before and after Hospital Discharge

Conservative Management of LVAD-Associated Ventricular Pseudoaneurysm

Durable left ventricular assist devices: a contemporary review of their benefits and drawbacks

Enhancing the implantation of mechanical circulatory support devices using computational simulations

Comparative analysis of regional outcomes and adverse events after continuous-flow left ventricular assist device implantation: An IMACS analysis

Outcomes and Complications after Left Ventricular Assist Device Implantation

Multicenter evaluation of left ventricular assist device implantation with or without ECMO bridge in cardiogenic shock

Left ventricular assist devices: A historical perspective at the intersection of medicine and engineering